Lavipharm S.A. (ATH: LAVI)

Market Cap	121.96M
Revenue (ttm)	51.34M
Net Income (ttm)	7.40M
Shares Out	168.69M
EPS (ttm)	0.04
PE Ratio	17.09
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	36,394
Open	0.720
Previous Close	0.720
Day's Range	0.720 - 0.739
52-Week Range	0.662 - 1.010
Beta	0.88
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About Lavipharm

Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, dermocosmetic, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and over the counter (OTC) products, as well as LIFELAB CBD. The company was founded in 1911 and is based in Paiania, Greece.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1911
• Employees: 307
• Stock Exchange: Athens Stock Exchange
• Ticker Symbol: LAVI

Financial Performance

In 2023, Lavipharm's revenue was 50.93 million, an increase of 30.40% compared to the previous year's 39.06 million. Earnings were 1.87 million, an increase of 124.34%.